Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Journal of Neurology|November 10, 2014
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTOREMichael Kaufman, Bruce A C Cree, Jerome De Sèze, et al.Neurology|April 1, 2014
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption studyRobert J Fox, Bruce A C Cree, Jerome De Sèze, et al.The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.Journal of Neurology|August 5, 2015
Predictors of disease activity in 857 patients with MS treated with interferon beta-1bHans-Peter Hartung, Ludwig Kappos, Douglas S Goodin, et al.Neurology|August 30, 2019
Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyMauricio F Farez, Jorge Correale, Melissa J Armstrong, et al.Neurology. Clinical Practice|September 6, 2021
Consensus Curriculum for Fellowship Training in Multiple Sclerosis and NeuroimmunologyLe H Hua, Ahmed Z Obeidat, Lilyana Amezcua, et al.Clinical Therapeutics|July 22, 2008
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot studyBarrie J Hurwitz, Douglas Jeffery, Barry Arnason, et al.The Lancet. Neurology|March 17, 2018
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extensionRaju Kapoor, Pei-Ran Ho, Nolan Campbell, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2018
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trialsDorothea Buck, Till Fm Andlauer, Wilmar Igl, et al.Journal of Neurology|May 16, 2009
Factors that influence adherence with disease-modifying therapy in MSKatherine Treadaway, Gary Cutter, Amber Salter, et al.Pageof 3